Cases That Test Your Skills

Afraid to leave home

Author and Disclosure Information

 

References

I slowly increase the frequency of my sessions with Mr. B from monthly to biweekly to weekly. We focus on strengthening the therapeutic alliance, motivational enhancement, emotional expression, and verbal identification of feeling states. We explore anxiety symptoms and psychosis using cognitive-behavioral therapy techniques informed by psychodynamic aspects of his experience, with the goal of resuming his prior level of functionality, including employment.

I carefully and slowly change Mr. B’s medications. First I increase his clozapine to 300 mg/d in 150 mg divided doses in an attempt to cover the possibility of residual paranoia, and for anxiolytic sedation without introducing a new medication. However, Mr. B’s anxiety symptoms worsen, so I resume the baseline dosage (125 mg bid). I choose not to switch to another antipsychotic because the risk for psychotic decompensation outweighs the potential benefits. I lower clonazepam to 2 mg/d in split doses. I teach Mr. B anxiety management techniques, including distraction, exposure, and anxiety tolerance training.

Because Mr. B refuses to start an SSRI for his anxiety symptoms, I prescribe bupropion and monitor him closely for dopamine agonism as evidenced by a re-emergence of psychosis. Once again, his anxiety symptoms worsen.

I stop bupropion and switch Mr. B to gabapentin, titrated to 400 mg tid. I chose this medication because of its sedation properties and relatively safe side effect profile. Mr. B was willing to try gabapentin—which was first approved to treat epilepsy—because he was afraid of having a seizure and also because it is not associated with sexual side effects. Furthermore, its GABA-mimetic actions made it a plausible alternative to replicate the benefits he was getting from clonazepam.

TREATMENT: An effective drug

Mr. B tolerates gabapentin well and his anxiety symptoms are much more sporadic, shorter, and more easily controlled by conscious exercise. The content of his thoughts is less disastrous and less ego-dystonic. He feels less dysphoria associated with clozapine and does not need as much clonazepam. He overcomes his avoidance of all fear-provoking triggers except walking across bridges.

Mr. B and I explore issues of object relationships and intimacy, establishing emotionally significant relationships with others, and the association between these and his distrust and paranoia. We also investigate the relationship between his criminal activity and feelings of loneliness or lack of control. Mr. B is able to verbalize positive and negative feelings and to feel in cognitive control of them.

Mr. B continues his regimen of clozapine, clonazepam, and gabapentin. He moves to independent housing and applies for employment.

Related resource

  • Garrett M, Lerman M. CBT for psychosis for long-term inpatients with a forensic history. Psychiatr Serv. 2007;58(5):712-713.
Drug brand names
  • Aripiprazole • Abilify
  • Bupropion • Wellbutrin
  • Clonazepam • Klonopin
  • Clozapine • Clozaril
  • Gabapentin • Neurontin
  • Olanzapine • Zyprexa
  • Ziprasidone • Geodon
Disclosure

The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

Pages

Recommended Reading

Person-Centered Care Decreases Agitation : Promoting choice, self-determination helps dementia patients without resorting to drugs.
MDedge Psychiatry
Oldest in LTC Less Likely to Have Serious Mental Illness
MDedge Psychiatry
Naltrexone Reduces Heavy Drinking, Smoking
MDedge Psychiatry
Alcohol Abuse May Lead to Depression
MDedge Psychiatry
Psychogenic Disorder Survey Shows Differences
MDedge Psychiatry
POLICY & PRACTICE
MDedge Psychiatry
On-Call Duties Usually Mean Additional Pay
MDedge Psychiatry
U.S. Launches AIDS Awareness Campaign
MDedge Psychiatry
Listen Up
MDedge Psychiatry
Clinical tips for managing safety in patients with borderline personality disorder
MDedge Psychiatry